Aptevo Therapeutics APVO shares are trading higher on Monday after the company said a second patient showed complete remission in its study for a treatment for acute myeloid leukemia.
Aptevo Therapeutics Inc is a biosciences company. The company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. Its pipeline product includes Otlertuzumab, APVO414, Multiple ADAPTIR Candidates, ALG.APV-527, APVO436 and APVO210.
Aptevo Therapeutics stock was trading up 33.88% at $31.73 on Monday during the time of publication. The stock has a 52-week high of $60 and a 52-week low of $2.94.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
